Tara Bancroft, an analyst from TD Cowen, maintained the Buy rating on Lantheus (LNTH – Research Report). The associated price target remains the same with $110.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Tara Bancroft’s rating is based on several strategic factors that highlight Lantheus’s potential for growth despite recent challenges. The company’s Q1 revenue was slightly below expectations due to pricing adjustments and temporary competitive pressures. However, Lantheus’s management has outlined plans to address these issues by expanding contracts with major accounts and increasing availability in underutilized segments, which are expected to drive market growth in the near term.
Moreover, Lantheus has slightly adjusted its 2025 revenue guidance, reflecting a more conservative outlook for Pylarify’s growth. This adjustment provides greater visibility into future performance, especially after the expiration of certain reimbursement schemes. Additionally, the divestment of its SPECT business is expected to allow Lantheus to focus on higher-growth opportunities, further supporting the Buy rating. These strategic moves suggest a positive long-term outlook for the company, justifying the Buy recommendation.
In another report released on May 5, Leerink Partners also maintained a Buy rating on the stock with a $139.00 price target.